Determination of glucose cut-off points for optimal performance of glucagon stimulation test

被引:1
作者
Kawalec, Joanna [1 ]
Horzelski, Wojciech [2 ]
Karbownik-Lewinska, Malgorzata [1 ,3 ]
Lewinski, Andrzej [1 ]
Lewandowski, Krzysztof C. [3 ,4 ]
机构
[1] Polish Mothers Mem Hosp, Res Inst, Dept Endocrinol & Metab Dis, Lodz, Poland
[2] Univ Lodz, Fac Math & Comp Sci, Lodz, Poland
[3] Med Univ Lodz, Dept Endocrinol & Metab Dis, Lodz, Poland
[4] Mazovian Univ Plock, Fac Med, Plock, Poland
关键词
glucagon stimulation test; growth hormone; cortisol; glucose; cut-off point; pituitary; pituitary function; INSULIN-INDUCED HYPOGLYCEMIA; ARGININE-VASOPRESSIN RESPONSE; GROWTH-HORMONE DEFICIENCY; POTENTIAL RISKS; TOLERANCE-TEST; SECRETION; DIAGNOSIS; COPEPTIN; INHIBITION; CORTISOL;
D O I
10.3389/fendo.2024.1448467
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The glucagon stimulation test (GST) is widely used to assess growth hormone (GH) and cortisol secretion, nevertheless the precise mechanisms underpinning these hormonal responses remain unclear. We have endeavoured to explore the relationship between glucose and insulin fluctuations during GST and their impact on GH and cortisol secretion. Subjects and methods: We retrospectively studied 139 subjects (mean age 35.5 +/- 15.1 years, BMI 26.6 +/- 6.61 kg/m(2)), including 62 individuals with a history of pituitary disease (27 with an intact adrenal axis) and 77 healthy controls. Standard dose intramuscular GST was performed in all subjects. Results: Once BMI and age were excluded from multivariate model, the nadir of glucose concentration during GST was the sole variable associated with maximal GH secretion (Delta GH, p<0.0003), while neither glucose/insulin peak, nor Delta glucose/Delta insulin concentrations contributed to Delta GH. 100% pass rate for GH secretion above 3 ng/ml or 1.07 ng/ml cut-offs was observed for glucose concentrations at, or below 60 mg/dl (3.33 mmol/l) (for Controls), or 62 mg/dl (3.44 mmol/l) (for Controls and patients with an intact adrenocortical axis). Such low glucose concentrations were obtained, however, only in about 30% of studied individuals. Conversely, cortisol secretion did not correlate with glucose or insulin fluctuations, suggesting alternative regulatory mechanisms. Conclusions: This study reveals that glucose nadir below 3.33 mmol/l is the only biochemical biovariable linked with optimal GH secretion during GST, whereas mechanisms responsible for cortisol secretion remain unclear. We emphasize the importance of glucose monitoring during GST to validate GH stimulation and support clinical decisions in GH deficiency management.
引用
收藏
页数:9
相关论文
共 36 条
[1]   Safety Assessment and Potential Risks of the Glucagon Stimulation Test in the Diagnosis of Secondary Adrenal Insufficiency [J].
Ach, Taieb ;
Ben Abdelkrim, Asma ;
Hasni, Yosra ;
Saad, Ghada ;
Kacem, Maha ;
Chaieb, Molka ;
Zaouali, Monia ;
Maaroufi, Amel ;
Ach, Koussay .
CURRENT DRUG SAFETY, 2022, 17 (01) :59-63
[2]   Interaction between glucagon and human corticotropin-releasing hormone or vasopressin on ACTH and cortisol secretion in humans [J].
Arvat, E ;
Maccagno, B ;
Ramunni, J ;
Maccario, M ;
Giordano, R ;
Broglio, F ;
Camanni, F ;
Ghigo, E .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 143 (01) :99-104
[3]   Interaction between glucagon and Hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans [J].
Arvat, E ;
Maccagno, B ;
Ramunni, J ;
Giordano, R ;
Broglio, F ;
Gianotti, L ;
Maccario, M ;
Camanni, F ;
Ghigo, E .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 143 (05) :601-606
[4]   The effect of glucose dynamics on plasma copeptin levels upon glucagon, arginine, and macimorelin stimulation in healthy adults Data from: Glucacop, Macicop, and CARGO study [J].
Atila, Cihan ;
Monnerat, Sophie ;
Urwyler, Sandrine Andrea ;
Refardt, Julie ;
Winzeler, Bettina ;
Christ-Crain, Mirjam .
PITUITARY, 2022, 25 (04) :636-644
[5]   Glucagon-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a double-blind, randomized, placebo-controlled study [J].
Atila, Cihan ;
Gaisl, Odile ;
Vogt, Deborah R. ;
Werlen, Laura ;
Szinnai, Gabor ;
Christ-Crain, Mirjam .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2022, 187 (01) :65-74
[6]   ENDOGENOUS OPIOID MEDIATION OF SOMATOSTATIN INHIBITION OF ARGININE VASOPRESSIN RELEASE EVOKED BY INSULIN-INDUCED HYPOGLYCEMIA IN MAN [J].
CHIODERA, P ;
COIRO, V .
JOURNAL OF NEURAL TRANSMISSION-GENERAL SECTION, 1991, 83 (1-2) :121-126
[7]   HYPOGLYCEMIA-INDUCED ARGININE VASOPRESSIN AND OXYTOCIN RELEASE IS MEDIATED BY GLUCORECEPTORS LOCATED INSIDE THE BLOOD-BRAIN-BARRIER [J].
CHIODERA, P ;
VOLPI, R ;
CAPRETTI, L ;
SPERONI, G ;
MARCATO, A ;
ROSSI, G ;
COIRO, V .
NEUROENDOCRINOLOGY, 1992, 55 (06) :655-659
[8]   THE INFUSION OF SOMATOSTATIN REDUCES THE ARGININE-VASOPRESSIN RESPONSE TO INSULIN-INDUCED HYPOGLYCEMIA IN MAN [J].
CHIODERA, P ;
GNUDI, A ;
BIANCONI, L ;
CAMELLINI, L ;
ROSSI, G ;
MUZZETTO, P ;
FAGNONI, F ;
SCHIANCHI, L ;
VOLPI, R ;
COIRO, V .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1989, 12 (05) :349-353
[9]   NICOTINIC-CHOLINERGIC INVOLVEMENT IN ARGININE-VASOPRESSIN RESPONSE TO INSULIN-INDUCED HYPOGLYCEMIA IN NORMAL MEN [J].
COIRO, V ;
BUTTURINI, U ;
GNUDI, A ;
DELSIGNORE, R ;
VOLPI, R ;
CHIODERA, P .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1986, 35 (07) :577-579
[10]   EFFECT OF OBESITY AND WEIGHT-LOSS ON THE ARGININE VASOPRESSIN RESPONSE TO INSULIN-INDUCED HYPOGLYCEMIA [J].
COIRO, V ;
CHIODERA, P .
CLINICAL ENDOCRINOLOGY, 1987, 27 (02) :253-258